Rocketseed drops release to boost email signature confidence on mobile for Microsoft 365 users
CHARLOTTE, N.C., June 6, 2025 /PRNewswire/ -- Rocketseed, a global leader in company email signature management software, has announced the upcoming launch of two major enhancements to its Microsoft 365 add-in feature, designed to improve user experience for both email senders and recipients. These new capabilities will be available to Microsoft 365 customers in coming weeks.
Rocketseed's Signature on Compose lets users preview their branded email signature directly in the compose window - giving full confidence it appears correctly before sending. The latest release extends this functionality to users of the Microsoft Outlook mobile app on iOS and Android, meeting demand from users composing and sending emails on the go.
The update also introduces embedded image support, ensuring all visual elements - logos, banners, social icons - display instantly and correctly, with no need for recipients to download. This marks a significant improvement over using referenced images on mobile devices, which was the only option until the recent update to the Microsoft API.
"These enhancements are a major step forward for both email senders and recipients," said Janine Ferenčak, Managing Director at Rocketseed. "With full support for Microsoft 365 and Outlook mobile apps, users can now see exactly how their email signature will appear before sending, ensuring brand consistency, especially on mobile. Meanwhile, embedded image support guarantees a perfect display for recipients."
These Rocketseed updates are available exclusively for Microsoft 365 customers. To implement, a company's Microsoft 365 administrator can request a manifest file from Rocketseed, enabling them to deploy the new functionality across their organization.
When a user composes a message, Rocketseed identifies the sender and automatically applies their pre-assigned signature, offering a tailored choice of a full version or a simplified version for email reply chains according to company policy. Signatures are managed centrally and rendered in real time, ensuring brand consistency and user flexibility.
With these new features, Rocketseed continues to lead the way in email signature software, delivering enterprise-grade tools for brand management, compliance, and marketing across every business email - including mobile.
About RocketseedRocketseed is a leading provider of email signature management and marketing solutions, used and trusted by businesses worldwide. With tools for centralized signature control, automated updates, targeted banner campaigns, and robust analytics, Rocketseed helps organizations maintain brand consistency, drive engagement, and ensure compliance — all through their everyday email. Learn more at www.rocketseed.com.
Press ContactJennifer BassettJenny.bassett@rocketseed.com+447800547354
View original content to download multimedia:https://www.prnewswire.com/news-releases/rocketseed-drops-release-to-boost-email-signature-confidence-on-mobile-for-microsoft-365-users-302475023.html
SOURCE Rocketseed (United States) Inc
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Apple reportedly ditching its OS naming system for something more... confusing?
When you buy through links on our articles, Future and its syndication partners may earn a commission. Quick Summary Apple is set to rip up the copybook when it comes to the names of its new OS updates. Industry sources claim the next iOS will be called iOS 26. Apple's other operating systems will follow suit, it is said. If you own an Apple device you'll likely be au fait with the company's OS naming system. We're currently on variants of iOS 18, iPadOS 18, tvOS 18, etc, and iOS 19 and we're fully expecting iOS 19 and its equivalents to be announced during WWDC in a couple of weeks. However, it turns out we could be very wrong. It is claimed that Apple is set to shake-up the naming convention for the software coming to its best iPhones and other devices. And rather than simplify things, it could be more baffling than ever. Bloomberg's resident Apple expert, Mark Gurman, has reported that Apple will switch to yearly identifiers from this year's OS updates. However, much like EA does with its annual EA Sports games, it'll opt for the forthcoming year, not the current one. According to "people with knowledge of the matter", that means we'll get iOS 26, iPadOS 26, macOS 26, watchOS 26, tvOS 26 and visionOS 26 this year, while next year will see iOS 27 release, and so on. The software will be the same as the rumoured iOS 19, etc, but the name will be different. Of course, once we get into the swing of it, it'll make sense. And we get why Apple would want to use the proceeding year rather than current one, considering each OS is likely to release towards the end of 2025 (in September). However, it could make it particularly confusing when scanning through app compatibility, for example. The jump from 19 to 26 leaves quite a gap for the uninitiated. It's also been pointed out just how Samsung this all seems. Samsung has, since 2020, named its flagship Android phones after years – although as they launch in February or March, they use the current date. The Samsung Galaxy S25 family is the latest, therefore. It doesn't do so with its software though, with One UI 8 (based on Android 16) set to be its next big phone OS release. We'll find out more about the new naming structure on 9 June during during Apple's WWDC 25 opening keynote (or should that be 26?).
Yahoo
an hour ago
- Yahoo
Apple teases iOS redesign in WWDC 25 clip
When you buy through links on our articles, Future and its syndication partners may earn a commission. Quick Summary Apple's changes to iOS may be clearer after a new tease. We're expecting something inspired by the Apple Vision Pro. It's a jubilant time of year of year for Apple fans. The brand will be hosting its annual Worldwide Developers Conference (WWDC) on Monday 9th June. That event has historically played host to a wide range of new software and operating system-based goodies. The brand often utilises its opening keynote speech as a platform to introduce new software for every part of its portfolio. All of the rumours and leaks so far have pointed to a new design, which will take on the glass-like aesthetic seen in the Apple Vision Pro's VisionOS. And the latest teaser from the brand seems to support that theory. The WWDC website has been changed to offer a new tagline. That reads 'Sleek Peak' and is topped by an Apple logo which appears to be made from frosted glass. It should be an exciting update. Everything in the in the Apple catalogue from the Apple Watch to the iPad and the iPhone to the Mac is expected to receive the update, and we'd expect them all to make use of this theme in some way. I think that's a much needed update. The brand has always been known for sleek, classy and minimal designs, and this embodies that perfectly. Keeping the design consistent across all of its products would also help to tie the entire ecosystem together a little more. It's not the only big change expected either. Earlier rumours suggested that the brand is set to change the numbering convention of its software, to better align with the year. That means that we'll see all of the various operating systems released as xOS 26 this time out. There's not too much else to go on right now – Apple has always been pretty good at keeping things under wraps. Still, with less than a week to go before the show takes place, there's not much longer to wait for the news direct from the source.
Yahoo
an hour ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme（the tradename of Merck & Co., Inc., Rahway, NJ, USA）is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy； OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy； OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
